methyl 2-(3-ethoxy-4-isopropoxyphenyl)-2-hydroxyacetate | 745019-93-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: methyl 2-(3-ethoxy-4-isopropoxyphenyl)-2-hydroxyacetate
• 英文别名: methyl 2-(3-ethoxy-4-propan-2-yloxyphenyl)-2-hydroxyacetate
• CAS: 745019-93-6
• 化学式: C₁₄H₂₀O₅
• 分子量: 268.31
• InChiKey: DTJIRLYTNVFGMO-UHFFFAOYSA-N

物化性质

• 沸点：
  379.4±42.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-(3-ethoxy-4-isopropoxyphenyl)-2-hydroxyacetate 在 palladium 10% on activated carbon 、 水 、 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 caesium carbonate 、 一水合肼 、 甲基磺酰氯 、 三乙胺 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 90.0 ℃ 、413.7 kPa 条件下， 反应 17.0h， 生成 2-[(3-amino-1H-indazol-6-yl)amino]-N-(benzenesulfonyl)-2-(3-ethoxy-4-propan-2-yloxyphenyl)acetamide
  参考文献：
  名称：

  Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors

  摘要：

  Aminoisoquinoline and isoquinoline groups have successfully replaced the more basic P1 benzamidine group of an acylsulfonamide factor Vila inhibitor. Inhibitory activity was optimized by the identification of additional hydrophobic and hydrophilic P' binding interactions. The molecular details of these interactions were elucidated by X-ray crystallography and molecular modeling. We also show that decreasing the basicity of the P1 group results in improved oral bioavailability in this chemotype. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.027
• 作为产物：
  描述：

  3-乙氧基-4-异丙氧基苯甲醛 在 盐酸 、 sodium hydrogensulfite 作用下， 以 乙酸乙酯 为溶剂， 反应 49.0h， 生成 methyl 2-(3-ethoxy-4-isopropoxyphenyl)-2-hydroxyacetate
  参考文献：
  名称：

  Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors

  摘要：

  Aminoisoquinoline and isoquinoline groups have successfully replaced the more basic P1 benzamidine group of an acylsulfonamide factor Vila inhibitor. Inhibitory activity was optimized by the identification of additional hydrophobic and hydrophilic P' binding interactions. The molecular details of these interactions were elucidated by X-ray crystallography and molecular modeling. We also show that decreasing the basicity of the P1 group results in improved oral bioavailability in this chemotype. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.027

文献信息

• Phenylglycine derivatives useful as serine protease inhibitors
  申请人：——

  公开号：US20040204412A1

  公开（公告）日：2004-10-14

  Compounds having the formula (I), 1 or a stereoisomer or pharmaceutically-acceptable salt, or hydrate thereof, are useful as factor VIIa inhibitors, wherein X is —NR 6 S(O) p R 16 ; W is hydrogen or —(CR 7 R 8 ) q W 1 ; W 1 is hydrogen or a bond with R 6 ; Z is a 5 -membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R 1 , R 2 , R 3 , R 6 , R 7 , and R 16 are as defined in the specification.

  具有公式（I）的化合物，或其立体异构体或药学上可接受的盐或水合物，可用作因子VIIa抑制剂，其中X为—NR6S(O)pR16；W为氢或—(CR7R8)qW1；W1为氢或与R6相连的键；Z为5-成员杂芳基团，五至六成员杂环或环烷基团，9-至10-成员双环芳基或杂芳基，或六成员芳基或杂芳基，而R1、R2、R3、R6、R7和R16如说明书所定义。
• 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Nirschl Alexandra A.

  公开号：US20090131473A1

  公开（公告）日：2009-05-21

  The present invention relates generally to novel 2-(aryloxy)acetamides of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables W, Y, Z, R 7 , R 8 , and R 9 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

  本发明涉及一般而言公式（I）的新型2-(芳氧基)乙酰胺或其立体异构体、互变异构体、药学上可接受的盐、溶剂化物或前药，其中变量W、Y、Z、R7、R8和R9如本文所定义。这些化合物是选择性抑制丝氨酸蛋白酶凝血因子VIIa的药物。
• Benzene acetamide compounds useful as serine protease inhibitors
  申请人：——

  公开号：US20040176375A1

  公开（公告）日：2004-09-09

  Compounds having the formula (I), 1 and pharmaceutically-acceptable salts, hydrates, or prodrugs thereof, are useful as serine protease inhibitors, wherein X is —OH, —O(alkyl), —O(aryl), —O(arylalkyl), —NR 5 (aryl), or —NR 5 (arylalkyl); W is hydrogen or —(CR 7 R 8 ) q —W 1 ; W 1 is hydrogen or a bond with R 6 ; Z is a 5-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , and R 16 are as defined in the specification.

  具有式(I)的化合物、 1 及其药学上可接受的盐、水合物或原药可用作丝氨酸蛋白酶抑制剂，其中 X 是 -OH、-O（烷基）、-O（芳基）、-O（芳烷基）、-NR 5 (芳基），或-NR 5 (芳烷基）；W 是氢或-(CR 7 R 8 ) q -W 1 ; W 1 是氢键或与 R 6 Z 是 5 个成员的杂芳基、5 至 6 个成员的杂环或环烷基、9 至 10 个成员的双环芳基或杂芳基、或 6 个成员的芳基或杂芳基，且 R 1 , R 2 , R 3 , R 5 , R 6 , R 7 和 R 16 的定义。
• WO2007/103996
  申请人：——

  公开号：——

  公开（公告）日：——
• PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1594505A2

  公开（公告）日：2005-11-16